Close Menu

NEW YORK – Based on growing evidence, some of which was presented earlier this month at the San Antonio Breast Cancer Symposium, Myriad Genetics believes that polygenic risk testing can be valuable not just in women who test negative for mutations in well-known breast cancer risk genes, but could significantly affect risk estimates for some mutation carriers as well.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.